Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595497 | 1.00 | SMYD3 (0.50) | SMYD3RAB9ANPC1KDRJAK2 | |
| SCHEMBL3609261 | 0.93 | RAB9A (0.52) | SMYD3RAB9ANPC1TLR9TLR8 | |
| SCHEMBL3609263 | 0.93 | RAB9A (0.52) | SMYD3RAB9ANPC1TLR9TLR8 | |
| SCHEMBL3605671 | 0.86 | SMYD3 (0.50) | SMYD3RAB9AKDRJAK2KDM1A | |
| SCHEMBL3605675 | 0.86 | SMYD3 (0.50) | SMYD3RAB9AKDRJAK2KDM1A | |
| SCHEMBL3611578 | 0.86 | SMYD3 (0.50) | SMYD3RAB9AKDRJAK2KDM1A | |
| SCHEMBL3607409 | 0.83 | SETD2 (0.48) | SMYD3KDM1A | |
| SCHEMBL3607407 | 0.83 | SETD2 (0.48) | SMYD3KDM1A | |
| SCHEMBL3601134 | 0.82 | KDM4E (0.53) | SMYD3RAB9ANPC1KDRKDM1A | |
| SCHEMBL3601131 | 0.82 | KDM4E (0.53) | SMYD3RAB9ANPC1KDRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SMYD3 811/4885RAB9A 3211/4885NPC1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.